title: Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
abstract: Several possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-alpha) and melphalan after isolated limb perfusion (ILP) have been presented. We found a significant sixfold increase in melphalan tumour tissue concentration after ILP when TNF-alpha was added to the perfusate, which provides a straightforward explanation for the observed synergism between melphalan and TNF-alpha in ILP.
authors.affiliation: Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt/Daniel den Hoed Cancer Centre, The Netherlands.
authors.forename: J H
authors.initials: JH
authors.lastname: de Wilt
authors.forename: T L
authors.initials: TL
authors.lastname: ten Hagen
authors.forename: G
authors.initials: G
authors.lastname: de Boeck
authors.forename: S T
authors.initials: ST
authors.lastname: van Tiel
authors.forename: E A
authors.initials: EA
authors.lastname: de Bruijn
authors.forename: A M
authors.initials: AM
authors.lastname: Eggermont
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D004357:Drug Synergism; D005121:Extremities; D008297:Male; D008558:Melphalan / Q000493:pharmacokinetics*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000378:metabolism*; D010477:Perfusion; D051381:Rats; D011914:Rats, Inbred BN; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan